NeuroVive Pharmaceutical ABの収入
NeuroVive Pharmaceutical ABの収入 は何ですか。
NeuroVive Pharmaceutical ABの収入 は-104.56krです。
収入 の定義は何ですか。
普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
OTCのセクタHealth Careにおける収入 の企業と比べるNeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical ABは何をしますか。
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
NeuroVive Pharmaceutical ABと類似の収入
- Wallfort Servicesの収入 は-104.93₨です。
- Strategic Trustの収入 は-104.90$です。
- Nuveen New Jersey Quality Municipal Income Fundの収入 は-104.79$です。
- Mersana Therapeutics Incの収入 は-104.77$です。
- abrdn Life Sciences Investorsの収入 は-104.60$です。
- BioAtlaの収入 は-104.56$です。
- NeuroVive Pharmaceutical ABの収入 は-104.56krです。
- PanAsialumの収入 は-104.55HKD$です。
- Purple Innovation Incの収入 は-104.53$です。
- AnPac Bio-Medical Science Co Ltdの収入 は-104.31¥です。
- Fusion Pharmaceuticalsの収入 は-104.28$です。
- Sofina SAの収入 は-104.26€です。
- Transcorp Internationalの収入 は-104.23₨です。